Clinical Trial Update: DPCP to Treat Cutaneous Neurofibromas Associated With NF1 [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating diphenylcyclopropenone (DPCP) for treating cutaneous neurofibromas in Neurofibromatosis Type 1 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Neurofibroma
• Neurofibromatosis Type

Drugs mentioned

• DPCP (Diphenylcyclopropenone)

Snippet

Sponsor: Nicholas Gulati | Conditions: Cutaneous Neurofibroma | Phase 1 | Status: COMPLETED